HIV-associated nephropathy is characterized by renal podocyte proliferation and dedifferentiation. This study found that all-trans retinoic acid (atRA) reverses the effects of HIV-1 infection in podocytes. Treatment with atRA reduced cell proliferation rate by causing G1 arrest and restored the expression of the differentiation markers (synaptopodin, nephrin, podocin, and WT-1) in HIV-1-infected podocytes. It is interesting that both atRA and 9-cis RA increased intracellular cAMP levels in podocytes. Podocytes expressed most isoforms of retinoic acid receptors (RAR) and retinoid X receptors (RXR) with the exception of RXR␥. RAR␣ antagonists blocked atRA-induced cAMP production and its antiproliferative and prodifferentiation effects on podocytes, suggesting that RAR␣ is required. For determination of the effect of increased intracellular cAMP on HIV-infected podocytes, cells were stimulated with either forskolin or 8-bromo-cAMP. Both compounds inhibited cell proliferation significantly and restored synaptopodin expression in HIV-infected podocytes. The effects of atRA were abolished by Rp-cAMP, an inhibitor of the cAMP/protein kinase A pathway and were enhanced by rolipram, an inhibitor of phosphodiesterase 4, suggesting that the antiproliferative and prodifferentiation effects of atRA on HIV-infected podocytes are cAMP dependent. Furthermore, both atRA and forskolin suppressed HIV-induced mitogen-activated protein kinase 1 and 2 and Stat3 phosphorylation. In vivo, atRA reduced proteinuria, cell proliferation, and glomerulosclerosis in HIV-1-transgenic mice. These findings suggest that atRA reverses the abnormal phenotype in HIV-1-infected podocytes by stimulating RAR␣-mediated intracellular cAMP production. These results demonstrate the mechanism by which atRA reverses the proliferation of podocytes that is induced by HIV-1.
H IV-associated nephropathy (HIVAN) is the most common cause of chronic renal failure in HIV-1-seropositive patients (1) . The key histologic features of HIVAN are collapsing FSGS and microcystic tubular dilation (2) . A unique characteristic of HIVAN is that podocytes, which normally are quiescent and highly differentiated cells, undergo marked proliferation and dedifferentiation (3, 4) . Expression of HIV-1 viral proteins is critical for pathogenesis as shown in HIV-1-transgenic mice (Tg26) as well as humans (5, 6) . Podocytes from HIV-1-transgenic mice exhibit increased growth rate and loss of contact inhibition when compared with those of control littermates (7) . In vitro, infection of podocytes with HIV-1 also causes proliferation and dedifferentiation (8) . We have shown that the HIV-1 nef gene is the major determinant of podocyte proliferation and dedifferentiation (8, 9) by inducing Src-dependent mitogen-activated protein kinase (MAPK) 1 and 2/Stat3 activation (10) .
Retinoids are derivatives of vitamin A and have multiple cellular functions, including inhibition of proliferation, induction of cell differentiation, regulation of apoptosis, and inhibition of inflammation (11) . During kidney development, retinoic acid (RA) affects tubulogenesis and nephron number (12) . In addition to their established benefits in treating some malignancies, retinoids have been found to provide protection in several experimental models of kidney disease (13) (14) (15) (16) . In rat models of acute and chronic mesangioproliferative glomerulonephritis, retinoids preserve renal function, decrease albuminuria, and reduce glomerular and tubular damage (13, 14) . In the rat model of puromycin aminonucleoside-induced nephrosis, retinoids prevent proteinuria from developing by protecting podocytes from injury (15, 16) .
Retinoids exert their effects by binding two families of nuclear receptors, retinoic acid receptors (RAR) and retinoid X receptors (RXR). All-trans-RA (atRA) binds and activates the RAR (RAR ␣, ␤, and ␥), whereas 9-cis RA binds and activates both the RAR and the RXR (RXR ␣, ␤, and ␥) (17) . RAR are expressed in many tissues, including the kidney (18) . They affect gene transcription either directly by binding to the RA-response elements of a pro-moter region (18, 19) or indirectly by modulating transcription factors such as activator-protein 1 (20, 21) or NF-B (22) . Activation of cytosolic signaling molecules by retinoids also has been reported as an important pathway to induce leukemia cell differentiation (23) . Retinoids directly alter the activity of various protein kinases, including MAPK and protein kinase C isoforms (24, 25) . A recent study reported that atRA induced rapid cAMP production and increases protein kinase A (PKA) activity in acute myeloblastic leukemia cells, leading to cell differentiation (26) . A synergistic effect between atRA and inhibitors of phosphodiesterase also was observed for myeloid differentiation (27) .
On the basis of the antiproliferative nature of atRA and the pathogenesis of HIVAN (podocyte proliferation and dedifferentiation), we hypothesized that retinoids may exert a beneficial effect on podocytes that are infected with HIV-1. In this study, we show that atRA can inhibit HIV-1-induced podocyte proliferation and dedifferentiation through activation of an RAR␣-mediated cAMP/PKA pathway.
Materials and Methods

Infection of Conditionally Immortalized Murine Podocytes with HIV-1 Expressing or Control Vector
Conditionally immortalized murine podocytes were isolated as described previously (28) . These cells proliferate under permissive conditions (IFN-␥ at 33°C) but differentiate under nonpermissive conditions (37°C). Mockor HIV-1-infected podocytes were plated on collagen-coated six-well plates at 80% confluence. Cells were cultured further with or without atRA (10 M). Photographs were taken on day 7. C. Dosage response of retinoids on podocyte proliferation. After differentiation, control podocytes (ࡗ) and HIV-infected podocytes (f) were incubated in collagen-coated dishes for 3 d with or without atRA at concentrations of 0.1, 0.5, 1, or 10 M. Cell number was counted. Means Ϯ SD of three independent experiments are shown. *P Ͻ 0.001 verus cells without atRA treatment. (D) Effects of atRA on mRNA expression levels of WT-1, synaptopodin, cyclin A, cyclin E, and glyceraldehyde-3-phosphate dehydrogenase (G3PDH). Normal podocytes (Mock) or HIV-1-infected podocytes (HIV) were cultured for 3 d with or without atRA (10 M). Total RNA (10 g/lane) was analyzed by Northern blotting. This is a representative blot of three independent experiments. (E) Dosage response of retinoids on synaptopodin expression. HIV-infected podocytes were treated with various concentrations (0.1 to 10 M) of atRA or 9-cis-RA for 3 d. Total RNA (10 g/lane) was analyzed by Northern blotting for synaptopodin and GAPDH. This is a representative blot of three independent experiments. (F) Effects of atRA on podocin expression. HIV-infected podocytes were treated with atRA (1 M) for 3 d. Podocin expression was determined by Western blot using anti-podocin antibody. This is a representative blot of three independent experiments. (G) Effects of atRA on nephrin expression. HIV-infected podocytes were treated with atRA (1 M) for 3 d. Nephrin/tubulin ratios were determined by real-time PCR. The fold of increased as compared with control podocytes are expressed. *P Ͻ 0.05 versus control (CL); **P Ͻ 0.05 versus HIV-infected podocytes; n ϭ 3. Magnification, ϫ200.
The HIV-1 constructs were described previously (8) . Briefly, the HIV-1 gag/pol deleted construct pNL4 -3:d1443 was derived from the provirus pNL4 -3. A fragment that contained the EGFP gene (from pEGFP-C1; Clontech, Palo Alto, CA) was inserted at the SphI/MscI gag/pol deletion site. The expression of HIV-1 genes was confirmed by Western blot analysis. The HIV-1 gag/pol genes and VSV.G envelope glycoprotein were provided in trans using pCMV R8.91 and pMD.G plasmids, respectively (gifts of Dr. Didier Trono, Salk Institute, La Jolla, CA). As a negative control, virus also was produced from pHR-CMV-IRES2-GFP-⌬B, which contains the HIV-1 long-term repeat and EGFP. As the pilot study, we performed experiments in both freshly infected podocytes and a subset of established podocytes. We obtained similar results; therefore, we used here the established HIV-infected podocytes. In all experiments, cells were grown at 37°C on type 1 collagen-coated dishes for 10 d to inactivate the temperature-sensitive T antigen and to allow for differentiation. By Western blot, we confirmed that T antigen was absent in these cells.
Cell Growth Assay
Control and HIV-1-infected podocytes were plated on collagencoated 24-well plates at a density of 20,000 cells/well. Podocytes were cultured further for 3 to 5 d with atRA or 9-cis RA (0.1 to 10 M; Sigma, St. Louis, MO), RAR␣ agonists (Am580 and Ro-23-4217), RAR␣ antagonist, and RXR agonist Ro-25-7386, and 4-hydroxyphenylretinamide, a poor activator of RAR, which served as a negative control (Roche, Basel, Switzerland) (29) . For testing of PKA pathway involvement, podocytes were cultured with H89 (10 M; Calbiochem, San Diego, CA), rolipram (10 M; Calbiochem), Rp-cAMP (100M; Sigma), Forskolin (Sigma), or various combinations as indicated in the figures. Vehicle alone served as a control. After intervention, cells were trypsinized and counted. For studying contact inhibition, podocytes were cultured for 10 d under nonpermissive conditions and were plated at 80% confluence on collagencoated dishes. Podocytes were cultured further with atRA (10 M) or vehicle (DMSO), and photographs were taken on day 7. 3-(4,5-dimethylthiazol)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay for cell proliferation also was performed after 3 d using a protocol that was provided by manufacturer (Promega, Madison, WI).
Figure 2.
(A and B) atRA stimulates intracellular cAMP production. After differentiation at 37°C, control podocytes (A) and HIV-infected podocytes (B) were cultured on collagen-coated six-well dishes and were stimulated with atRA (10 M) for 2, 5, 10, 20, and 30 min with or without preincubation with rolipram (100 M). Intracellular cAMP levels were determined using ELISA. The representative experiment of three independent assays is shown. (C and D) Dosage response of atRA and 9-cis-RA on cAMP production. Control podocytes were cultured on collagen-coated six-well dishes and were stimulated with various concentration of atRA or 9-cis-RA for 2, 5, and 10 min after preincubation with rolipram (100 M). The representative experiment of three independent assays is shown. 
Flow Cytometry
After virus infection, podocytes were cultured under nonpermissive conditions for 10 d and then incubated with atRA (10 M) or vehicle for 4 additional days. Cells were trypsinized, washed with 1ϫ PBS, and fixed with ice-cold 80% ethanol. Cells were pelleted, resuspended in 1ϫ PBS, and passed through a 25-G needle to create a single suspension. RNase (1 mg/ml) and propidium iodine (400 g/ml) were added, and cells were incubated for 30 min at 37°C. Cell-cycle analysis was performed on a FACSCalibur flow cytometer, and data were analyzed with CellQuest software (Becton Dickinson, Mountain View, CA).
Apoptosis Study
Apoptosis was determined by Annexin V FITC apoptosis detection kit (BD Bioscience, San Jose, CA). This combined staining using An- nexin V and propidium iodide allowed us to distinguish early apoptotic cells from necrotic or later apoptotic cells. After staining, apoptotic cells were measured by flow cytometry.
Northern Blot Analysis
Total RNA was extracted using Trizol (Life Technologies BRL, Grand Island, NY). Probes were generated by reverse transcriptase-PCR of RNA that were isolated from glomeruli of a normal mouse. The cDNA probes were radiolabeled with [ 32 P-␣] dCTP by random oligonucleotide priming and hybridized either with Hybrisol (Intergen, Purchase, NY) or with ULTRAhyb (Ambion, Austin, TX).
Real-Time PCR
Real-time PCR was performed with a Roche LightCycler with a Qiagen QuantiTect One Step RTPCR SYBR green kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Validated primer sets for nephrin and tubulin were obtained from Qiagen. Melting-curve analysis was performed to check for a single amplicon that was verified by size using gel electrophoresis. LightCycler analysis software was used for determining crossing points using the second derivative method. Data were analyzed by the 2 Ϫ⌬⌬ C T method as described by Livak and Schmittgen (30) and are presented as fold increase normalized to housekeeping genes.
Assay for cAMP
Intracellular cAMP was measured using a cAMP Biotrak enzyme immunoassay system (Amersham Biosciences, Piscataway, NJ). After being serum-starved overnight, cells were stimulated with different analogs of retinoids (0.1 to 10 M) with or without rolipram (10 M) for 2, 5, 10, and 30 min as indicated. Cells were lysed, and 100 l of cell lysates was used for the assay. A nonacetylation enzyme immunoassay procedure was used to measured intracellular cAMP production with a standard curve in a range from 12.5 to 3200 fmol/well.
Western Blot
Podocytes were lysed with a buffer that contained 1% NP40, a protease inhibitor cocktail and tyrosine and serine-threonine phosphorylation inhibitors. Cell lysates were subjected to Western blot analysis using the following specific antibodies: Anti-phospho-MAPK1,2, anti-MAPK1,2, anti-phospho-Stat3, and anti-Stat3 from Cell Signaling Laboratory (Beverly, MA). Anti-Nef antibody was obtained from FIT Biotech Oyj Plc (Tampere, Finland). Anti-podocin antibody was a gift from Dr. Peter Mundel (Mount Sinai School of Medicine, NY).
In Vivo Studies
Experimental Design. Tg26 and their littermates were given intraperitoneal injection of atRA at 16 mg/kg or vehicle alone (corn oil) three times per week from 10 d of age to 4 mo of age (five mice per group).
Urine Analysis. Urine was collected at 20-d intervals. Urine was assayed for protein excretion using sulfosalicylic acid and creatinine excretion using a colorimetric microplate assay based on the Jaffe reaction (Oxford Biomedical Research, Oxford, MI).
Histology and Sclerosis Scoring. Kidney tissue was collected at 120 d and fixed in formalin or methyl Carnoy fixed tissue. Periodic acid-Schiff staining was performed. A glomerulosclerosis index and interstitial disease index were measured on tissue from all animals. A total of 50 glomeruli were observed per tissue sample, and the percentage of segmental sclerosis was recorded as 0, 0 to 25, 25 to 50, 50 to 75, or 75 to 100%. Collapsed glomerular tufts also were recorded. The degree of interstitial disease, mostly tubular dilation, was recorded as an overall impression of the biopsy with the same percentage range.
Immunohistochemical analysis for nuclear cell proliferation-associated antigen (Ki67) to assess proliferation was performed with mouse anti-Ki67 1:100 (BD Pharmingen, San Diego, CA) and followed by biotinylated horse anti-mouse IgG antibodies (1:100; both from Vector Laboratories, Burlingame, CA). The ABC elite kit was used to enhance the signal, and staining was visualized by reaction with 3,3Ј-diaminobenzidine. The number of Ki67-positive nuclei per glomerulus was scored in a total of 50 glomeruli per mouse.
Statistical Analyses
For the cell proliferation and cAMP assays, the data are means Ϯ SD of the mean. For Northern blot and Western blot analysis, all experiments were repeated at least three times. Representative experiments are shown below. Statistically significant differences between the means were determined by unpaired t test or the Mann-Whitney U test where appropriate. Significance was defined as a P Յ 0.05.
Results
RA Inhibits Proliferation and Restores Differentiation Markers in HIV-1-Infected Podocytes
We found that atRA (10 M) markedly decreased cell proliferation rate in both control and HIV-1-infected podocytes ( Figure  1A ). There was no nuclear fragmentation in the cells that were treated with up to 10 M atRA, suggesting that cell toxicity or increased apoptosis was not responsible for these findings. This was confirmed further by analysis of apoptosis cells using Annexin V and propidium iodide staining. The antiproliferative effects of atRA were reversible because HIV-infected podocytes recovered a high growth rate when atRA was removed from culture medium (data not shown). atRA (10 M) also inhibited the contact-independent growth of podocytes that was induced by HIV-1 infection ( Figure 1B) . Podocytes that were treated with atRA were enlarged and grew in a monolayer, suggesting that these cells had converted back to a more differentiated state. For further exploration of the effective dosage of atRA on podocyte proliferation, both control and HIV-infected podocytes were incu- bated with atRA at different concentrations. We found that atRA significantly inhibited HIV-induced proliferation at 0.5 M (Figure 1C) .
FACS analysis was performed on HIV-1-and mock-infected podocytes that were treated with atRA for 7 d. As shown in Table 1 , the percentage of HIV-1-infected podocytes in the G 0 /G 1 phase was one third that of mock-infected podocytes (22.1 versus 61%). Treatment of HIV-1-infected podocytes with atRA resulted in an increase in the percentage of cells in G 1 to 53.6% with a decrease in the fraction of cells in the S phase. These results demonstrate that atRA inhibits the proliferation of HIV-1-infected podocytes by inducing G 1 arrest.
RA has been shown to inhibit G 1 -to-S transition by regulating the expression of cell-cycle proteins (31, 32) . We found that atRA inhibited the transcription of cyclin A and cyclin E in HIV-1-infected podocytes ( Figure 1D ). These findings suggest that atRA blocks HIV-1-induced G 1 3 S progression through downregulation of cyclin A and cyclin E expression.
Because HIV-1 infection also is known to suppress expression of podocyte differentiation markers, we examined whether atRA could reverse these effects as well. HIV-1-infected podocytes were treated with atRA (10 M) or vehicle for 3 d. As shown by Northern blot, atRA significantly increased the mRNA levels of WT-1 and synaptopodin in HIV-infected podocytes ( Figure 1D ). The effect of atRA and 9-cis RA on synaptopodin expression was dosage dependent, as shown in Figure   1E . By real-time PCR, we found that nephrin mRNA levels also increased after atRA treatment in both control and HIV-infected podocytes ( Figure 1E) . Similarly, Western blot analysis showed that atRA stimulated podocin expression in both control and HIV-infected podocytes ( Figure 1F ). These data suggest that treatment with atRA induces podocyte differentiation.
RA Induces a Rapid Increase in Intracellular cAMP in Podocytes through RAR␣
Recently, it was shown that atRA stimulates intracellular cAMP generation in leukemia cells, suggesting a critical cytosolic pathway for myeloid differentiation (26) . Because activation of the cAMP pathway generally is considered protective of injury in podocytes (33), we examined whether cAMP mediates the effects of atRA on podocytes. We found that atRA induced a three-to four-fold increase in intracellular cAMP production in control podocytes. This stimulation was amplified when cells were pretreated with rolipram, a phosphodiesterase 4 (PDE4) inhibitor (Figure 2A) . A similar pattern of stimulation was observed in HIV-1-infected podocytes ( Figure 2B ). Once again, stimulation of cAMP production by atRA and 9-cis RA were dosage dependent (Figure 2, C and D) .
Next, we investigated whether podocytes have retinoid receptors and whether these receptors mediate the actions of atRA on HIV-infected podocytes. By Northern blot, we found that podocytes express RAR␣, RAR␤, RAR␥, RXR␣, and RXR␤ ( Figure 3A) . We also found that HIV infection significantly suppressed expression of two major receptors in podocytes (RAR␣ and RXR␣; Figure 3A ). Using receptor-specific agonists and antagonists, we evaluated the roles of these receptors in mediating the effects of RA on podocytes. The RAR␣ antagonist (Ro-41-5253) blocked atRA-induced cAMP production ( Figure  3B) . Conversely, the RXR agonist (Ro-25-7386) had only a minor effect on atRA-induced cAMP production ( Figure 3C ). These data suggest that RAR␣ but not RXR mediates atRA-induced cAMP production. The mechanism by which this occurs remains to be determined. We examined whether RAR␣ also mediates the phenotypic effects of atRA on podocytes. As shown in Figure 3D , RAR␣ agonists (Am580 and Ro-23-4217) but not RXR agonist (Ro-25-7386) significantly inhibited HIVinduced proliferation, similar to atRA and 9-cis-RA. Furthermore, the RAR␣ antagonist Ro-41-5253 blocked the inhibitory effects of atRA. The RAR␣ agonists also restored expression of synaptopodin in HIV-infected podocytes similar to what was observed with atRA, and the RAR␣ antagonist blocked the effect of atRA on synaptopodin expression ( Figure 3E ). Therefore, although the expression is suppressed partially in HIVinfected podocytes, RAR␣ still plays a critical role in mediating the effects of retinoids on podocytes.
Activation of the cAMP/PKA Pathway by atRA Reverses HIV-1-Induced Proliferation and Dedifferentiation
Because atRA induces cAMP production in podocytes, we investigated whether activation of the cAMP/PKA pathway was sufficient to reverse the effects of HIV-1 on podocytes. HIV-1 podocytes were treated with forskolin (to stimulate adenylyl cyclase) or exogenous 8-bromo-cAMP (a cAMP analogue). Both compounds inhibited HIV-induced podocyte proliferation and restored the expression of synaptopodin (Figure 4 ). These data suggest that activation of the cAMP/PKA pathway could be the mechanism by which atRA reverses the effects of HIV-1 on podocytes Therefore, we examined whether the actions of atRA were mediated by activation of the cAMP/PKA pathway. Rp-cAMP (a competitor of endogenous cAMP) significantly diminished the inhibitory effect of atRA on HIV-1-induced podocyte proliferation as assessed by the MTS cell proliferation assay ( Figure 5A ) and cell counting ( Figure 5B ). Treatment of cells with both rolipram and atRA to increase cAMP production were additive in inhibiting podocyte proliferation ( Figure 5C ). We also found that Rp-cAMP blocked the ability of atRA to stimulate the expression of synaptopodin in HIV-infected podocytes, whereas the effects of atRA were enhanced by rolipram ( Figure 5D ). These data indicate that the activation of the cAMP pathway mediates the effects of atRA on podocytes.
atRA Inhibits HIV-Induced MAPK1,2 and Stat3 Phosphorylation
We reported previously that HIV stimulates the Ras/Raf/ MAPK1,2 pathway, leading to podocyte proliferation through Nef (10) . We examined whether atRA used a cross-talk mechanism with cAMP to affect MAPK1,2 phosphorylation in podocytes. It is interesting that both atRA and 9-cis RA decreased HIV-induced MAPK1,2 phosphorylation in a dosage-dependent manner ( Figure 6A ). Forskolin and 8-bromo-cAMP also inhibited HIV-induced MAPK1,2 phosphorylation ( Figure 6B ), whereas Rp-cAMP abolished the inhibitory effect of atRA on MAPK1,2 activation ( Figure 6C ). Together, these data indicate that atRA inhibits MAPK1,2 phosphorylation through activation of the cAMP pathway. We also found that both atRA and 9-cis-RA suppressed phosphorylation of Stat3 (Tyr705; Figure  6D ). As a control, we did not see changes in Nef expression in HIV-infected podocytes after atRA treatment ( Figure 6D ).
In Vivo Study
To confirm our in vitro findings, we examined whether treating HIV-1-transgenic mice (Tg26) with atRA ameliorates HIVassociated kidney disease. As shown in Figure 7 , Tg26 mice developed more proteinuria and glomerulosclerosis than their littermates. When Tg26 mice were treated with atRA, they exhibited significantly reduced proteinuria, cell proliferation, and glomerulosclerosis, compared with nontreated Tg26 mice. These data indicate that atRA exerts protective effects in vivo. 
Discussion atRA Changes HIV-Infected Podocytes from a Pathologic Phenotype to a More Differentiated Phenotype
This study demonstrates that atRA can reverse the pathologic changes that are observed in HIV-infected podocytes (cell dedifferentiation and proliferation) and in HIV-1-transgenic mice (proteinuria and glomerulosclerosis). Recently, retinoids were shown to improve kidney diseases in several experimental animal models, including anti-Thy-1 nephritis (13, 14) , puromycin aminonucleoside-induced nephrosis (15, 16) , lupus nephritis (34) , and anti-glomerular basement membrane nephritis (35, 36) . atRA prevents the decrease in synaptopodin, nephrin, and podocin staining in an anti-glomerular basement membrane glomerular injury model (36) .
HIV-associated nephropathy is characterized by podocyte proliferation, loss of contact inhibition, and dedifferentiation, similar to malignant cells (7) (8) (9) (10) . In this study, we found that RA blocked HIV-1-induced proliferation and contact-independent growth primarily through G 1 arrest and decreased expression of cyclin A and cyclin E in HIV-1-infected podocytes. atRA also induced podocyte differentiation manifested by increased expression of WT-1, nephrin, podocin, and synaptopodin. These findings provide a rationale for using RA to treat HIVAN and other diseases of podocyte proliferation, such as idiopathic collapsing FSGS.
atRA Reverses Abnormal Phenotype of HIV-Infected Podocytes through Stimulation of Intracellular cAMP Production
Several studies demonstrated that atRA induces rapid cAMP production and increases PKA activity in acute myeloblastic leukemia cells (26) . Our results demonstrate significant stimulation of cAMP production within minutes when podocytes are treated with either atRA or 9-cis-RA. This stimulation was amplified when cells were pretreated with rolipram, an inhibitor of PDE4. Podocytes express several G protein-coupled receptors (GPCR), including the ␤2-adrenergic receptor, the D1-dopamine receptor, and the prostaglandin IP and EP4 receptors (33, 37) . Activation of these receptors results in generation of intracellular cAMP. Induction of the cAMP-PKA pathway in podocytes regulates cell morphology, actin assembly, and matrix production (33) . In addition, cAMP seems to attenuate the effect of hormones that activate the Ca 2ϩ /PKC pathway (38) . Overall, the cAMP pathway seems to exert a protective effect on podocytes (33) . In this study, we found that the cAMP/PKA pathway mediates the beneficial effects of atRA on podocytes because Rp-cAMP blocked atRA-induced differentiation of podocytes. We also found that rolipram enhanced the atRA effect. These data indicate that atRA exerts its effect on HIV-1-infected podocytes through activation of the cAMP pathway. Treatment with atRA alone or in combination with PDE inhibitors could be an effective treatment strategy (in combination with antivirals) for HIVAN.
RAR␣ Mediates the Effects of atRA on HIV-Infected Podocytes
Although receptor-independent effects of retinoids have been described, most studies have shown that RAR and/or RXR play a role in retinoid-induced cellular effects through either genomic or nongenomic pathways (18, 24, 26) . It was surprising that RAR␣, which is suppressed in HIV-infected cells, still played a critical role in atRA's effects on podocyte phenotype as supported by our data using the RAR␣ agonist and antagonist. How RAR␣ mediates atRA-induced cAMP production, however, remains unclear. Estrogen can induce cAMP production through activation of adenylyl cyclase (39) , and a recent study suggested that estrogen binds to intracellular GPCR (40) . Further studies are required to determine whether there are GPCR that bind atRA.
atRA Inhibits HIV-Induced MAPK1,2 and Stat3 Phosphorylation
In previous studies, we found that HIV Nef induced MAPK1,2 and Stat3 activation in podocytes (10, 41) . Inhibition of MAPK1,2 or Stat3 activation suppressed Nef-induced cell proliferation and dedifferentiation (10) . Here, we found that atRA inhibited both MAPK1,2 and Stat3 phosphorylation in podocytes. atRA probably reduces MAPK phosphorylation through activation of MAPK phosphatase 1, as this was reported previously (42) . It has been reported that atRA can inhibit Stat3 activation in leukemia cells (43) .
Conclusion
We found that atRA inhibits proliferation and induces differentiation in HIV-infected podocytes through RAR␣-mediated cAMP/PKA activation. These data provide new insights into the underlying molecular mechanisms of the podocyte disease of HIVAN as well as a novel therapeutic strategy for its treatment.
